Partnerships & Announcements

Pfizer Ignite: Kathy Fernando’s vision for accelerating biotech innovation

Pfizer’s Aamir Malik on Next-Generation Medical Breakthroughs* | The Atlantic Festival 2023

Cardiff Oncology Announces New Lead Program in First-Line Metastatic Colorectal Cancer and Expanded Pfizer Relationship

Cardiff Oncology

Cardiff Oncology is a clinical-stage biotechnology company with the singular mission of developing new treatment options for cancer patients in indications with the greatest medical need.

CellCentric

CellCentric is a clinical stage biotech company focused on the development of a first of its kind, p300/CBP inhibitor to treat specific cancer types.

CellCentric announces $25m strategic investment from Pfizer

ORIC Pharmaceuticals Announces Clinical Development Collaboration with Pfizer for ORIC-533 in Multiple Myeloma and Concurrent $25 Million Equity Investment by Pfizer

ORIC Pharmaceuticals

ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer.

Carrick Therapeutics

Carrick Therapeutics is a clinical-stage biopharmaceutical company focused on building the future of oncological therapy to improve patient outcomes.

Carrick Therapeutics Announces $35 Million Investment from Pfizer

Anokion Announces $35 Million Equity Investment from Pfizer

Anokion

Anokion SA is a Swiss biotechnology company that aims to make a meaningful difference in the lives of patients suffering from autoimmune diseases by restoring normal immune tolerance. The company is focused on both prevalent and rare autoimmune diseases, including celiac disease, multiple sclerosis, and type 1 diabetes.